METHOTREXATE REDUCED TNF BIOACTIVITY BY ANTI-INFLIXIMAB ANTIBODY PREVENTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB

被引：0
|
作者：
Denarie, D. [1 ]
Rinaudo, M. [2 ]
Thomas, T. [1 ]
Paul, S. [2 ]
Marotte, H. [1 ]
机构：
[1] Chu St Etienne France, Rheumatol Unit, St Etienne, France
[2] Chu St Etienne France, Immunol & Immunomonitoring Dept, St Etienne, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.3296
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0109
引用
收藏
页码：459 / 459
页数：1
相关论文
共 50 条
  • [21] Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
    Haraoui, B
    Cameron, L
    Ouellet, M
    White, B
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 31 - 36
  • [22] Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
    Van Stappen, Thomas
    Brouwers, Els
    Tops, Sophie
    Geukens, Nick
    Vermeire, Severine
    Declerck, Paul J.
    Gils, Ann
    THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 479 - 485
  • [23] Etanercept -: infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFα
    Brocq, O
    Plubel, Y
    Breuil, V
    Grisot, C
    Flory, P
    Mousnier, A
    Euller-Ziegler, L
    PRESSE MEDICALE, 2002, 31 (39): : 1836 - 1839
  • [24] ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC DISEASES TREATED WITH INFLIXIMAB
    Kosmac, M.
    Toplak, N.
    Simonini, G.
    Cimaz, R.
    Serbec, V. Curin
    Avcin, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 255 - 255
  • [25] A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis
    van den Bemt, B. J. F.
    Vos, K.
    den Broeder, A. A.
    Blom, M.
    Thurlings, R. M.
    Bartelds, G. M.
    Stapel, S. O.
    Barrera, P.
    Tak, P. P.
    Nurmohamed, M. T.
    Wolbink, G-J
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (08) : 1368 - 1369
  • [26] Detection of anti-infliximab antibodies is of limited value to predict acquired drug resistance to infliximab in rheumatoid arthritis
    Finckh, Axel
    Dudler, Jean
    Wennelinger, Felix
    Ciurca, Adrian
    Gabay, Cem
    Bas, Sylvette
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S777 - S777
  • [27] Establishing an Anti-Infliximab Antibody (ATI) Threshold to Predict Infliximab Durability
    Greywoode, Ruby
    Dubinsky, Marla
    Spencer, Elizabeth
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S21 - S22
  • [28] Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    Fleischmann, RM
    Cohen, SB
    Moreland, LW
    Schiff, M
    Mease, PJ
    Smith, DB
    Keenan, G
    Kremer, JM
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) : 1181 - 1190
  • [29] Clinical significance of occurrence of autoantibodies in rheumatoid arthritis patients treated with infliximab and methotrexate
    Novak, S
    Anic, B
    Cikes, N
    Sentic, M
    Bosnic, D
    Budiselic, R
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 386 - 386
  • [30] Autoantibodies in rheumatoid arthritis patients treated with infliximab and methotrexate - One year follow
    Novak, S
    Anic, B
    Cikes, N
    Bosnic, D
    Sentic, M
    Budiselic, R
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 269 - 269
12345